文献速递湿疹皮炎与荨麻疹

外用磷酸二酯酶4抑制剂治疗轻中度特应性皮炎:系统评价与Meta分析

Application of Topical Phosphodiesterase 4 Inhibitors in Mild to Moderate Atopic Dermatitis: A Systematic Review and Meta-analysis.
PubMed 文献 · JAMA Dermatol · 2019-01-01

该系统评价与Meta分析纳入7项双盲随机对照试验共1869例轻中度特应性皮炎患者,比较外用PDE4抑制剂与赋形剂。结果显示PDE4抑制剂显著降低目标皮损评分(SMD -0.40,95%CI -0.61至-0.18,P<.001),提高研究者总体评估清除或几乎清除的应答率(RR 1.50,95%CI 1.33-1.70,P<.001),且治疗相关不良事件无差异。亚组分析显示获益主要见于克立硼罗和AN2898。

要点

  • 外用PDE4抑制剂可显著改善轻中度AD目标皮损评分和研究者总体评估应答率。
  • 治疗相关不良事件及导致停药的不良事件与赋形剂无差异。
  • 获益证据主要来自克立硼罗和AN2898,支持其用于维持或序贯治疗。

核心结论

  • 外用PDE4抑制剂是轻中度特应性皮炎安全有效的治疗选择。
  • 当前证据支持克立硼罗或AN2898作为轻中度AD的维持或序贯治疗选择。

研究设计与样本

  • 系统评价与Meta分析,纳入7项双盲随机对照试验,共1869例轻中度AD患者,比较外用PDE4抑制剂与赋形剂。
  • 检索MEDLINE、Embase、Cochrane对照试验注册库、中国医学数据库、ClinicalTrials.gov等,截至2018年8月15日,无语言限制。
  • 采用随机效应模型进行Meta分析,使用Cochrane协作网偏倚风险评估工具,漏斗图和Egger检验评估发表偏倚。

主要发现

  • 与赋形剂相比,外用PDE4抑制剂显著降低目标皮损评分(SMD -0.40;95%CI -0.61至-0.18;P<.001)。
  • 研究者评估清除或几乎清除的应答率显著更高(RR 1.50;95%CI 1.33-1.70;P<.001)。
  • 治疗相关不良事件及需要停药的不良事件无差异。
  • 亚组分析显示克立硼罗第14天SMD -0.59(95%CI -1.15至-0.02;P=.04),第28天SMD -0.86(95%CI -1.44至-0.28;P=.004)。
  • AN2898第14天SMD -0.76(95%CI -1.38至-0.13;P=.02),第28天SMD -0.68(95%CI -1.30至-0.05;P=.03)。

关键数值与推荐

  • 纳入标准为双盲随机临床试验,比较外用PDE4抑制剂与赋形剂治疗轻中度AD患者。
  • 主要结局为目标皮损评分较基线的变化,以标准化均数差(SMD)及95%CI表示。
  • 次要结局为研究者评估和安全性的相对风险(RR)及95%CI。

临床怎么用

  • 对于轻中度AD患者,可考虑外用PDE4抑制剂作为治疗选择。
  • 克立硼罗或AN2898可作为维持或序贯治疗方案。
  • 治疗14天和28天即可观察到目标皮损评分显著下降。

局限性

  • 获益证据主要限于克立硼罗和AN2898两种PDE4抑制剂。
  • 检索截止至2018年8月15日,未纳入此后发表的研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Topical medication is the central treatment for patients with atopic dermatitis (AD), but the options are limited. Phosphodiesterase 4 (PDE4) inhibitors are a new candidate for AD therapy. OBJECTIVE: To evaluate the efficacy and safety of topical PDE4 inhibitors in mild to moderate AD. DATA SOURCES: Clinical trials were identified from MEDLINE, Embase, Cochrane Controlled Register of Trials, Chinese medical databases (Wanfang, Chinese National Knowledge Infrastructure, Chinese Biomedical Literature Database, and China Science and Technology Journal Database), ClinicalTrials.gov, and other trial registries from inception to August 15, 2018. No restrictions on languages were placed. STUDY SELECTION: Only double-blind randomized clinical trials with topical PDE4 inhibitors vs topical vehicle treatment for patients with mild to moderate AD were included. DATA EXTRACTION AND SYNTHESIS: Two reviewers independently extracted study features, intervention details, and outcomes. A meta-analysis was performed using the random-effects model. The Cochrane Collaboration's risk of bias assessment tool was used to assess the risk of bias. Funnel plots and Egger tests were used to assess the publication bias. MAIN OUTCOMES AND MEASURES: Changes from baseline in target lesion score were expressed in terms of standardized mean differences (SMDs) with 95% CIs. Outcomes of investigators' assessment and safety were expressed in terms of relative risk with 95% CIs. RESULTS: Seven studies were identified, which included 1869 patients with mild to moderate AD. Overall, compared with the topical vehicle control, topical application of PDE4 inhibitors was associated with a significant decrease in target lesion score (SMD -0.40; 95% CI, -0.61 to -0.18; P < .001) and a higher response rate in investigators' assessment of clear or almost clear skin (relative risk, 1.50; 95% CI, 1.33-1.70; P < .001). There was no difference in treatment-related adverse events or in adverse events that required discontinuation of therapy. Subgroup analyses indicated that after 14 and 28 days of therapy with PDE4 inhibitors, target lesion score was significantly decreased. However, these beneficial effects were displayed only for the PDE4 inhibitors crisaborole and AN2898 (crisaborole at day 14: SMD, -0.59; 95% CI, -1.15 to -0.02; P = .04; AN2898 at day 14: SMD, -0.76; 95% CI, -1.38 to -0.13; P = .02; crisaborole at day 28: SMD, -0.86; 95% CI, -1.44 to -0.28; P = .004; AN2898 at day 28: SMD, -0.68; 95% CI, -1.30 to -0.05; P = .03). Heterogeneity was not significant across studies. CONCLUSIONS AND RELEVANCE: This meta-analysis suggests that topical PDE4 inhibitors are a safe and effective treatment for mild to moderate AD. Current evidence supports the use of crisaborole or AN2898 as the choice of maintenance or sequential therapy for mild to moderate AD.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Yang H, Wang J, Zhang X, et al. Application of Topical Phosphodiesterase 4 Inhibitors in Mild to Moderate Atopic Dermatitis: A Systematic Review and Meta-analysis. JAMA Dermatol. 2019. PMID: 30916723. doi:10.1001/jamadermatol.2019.0008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。